

a hydrogen atom or a C_nsub.1-6 alkyl group; or R₁sub.1 and R₂sub.1 may together represent an alkyne chain -(C_nsub.2).sub.n —, where n represents 1, 2 or 3; one of the groups represented by R₁sub.5, R₁sub.6 and R₁sub.7 is a hydrogen atom or a C_nsub.1-6 alkyl, C_nsub.3-7 cycloalkyl, C_nsub.3-6 alkenyl, phenyl or phenylC_nsub.1-3 alkyl group, and each of the other two groups, which may be the same or different, represents a hydrogen atom or a C_nsub.1-6 alkyl group; G represents a hydrogen atom or a halogen atom or a hydroxy, C_nsub.1-4 alkoxy, phenylC_nsub.1-3 alkoxy or C_nsub.1-6 alkyl group or a group -NR₁₀sub.10 R₁₁sub.11 or -CONR₁₀sub.10 R₁₁sub.11 (wherein R₁₀sub.10 and R₁₁sub.11, which may be the same or different, each represents a hydrogen atom or a C_nsub.1-4 alkyl or C_nsub.3-4 alkenyl group, or together with the nitrogen atom to which they are attached form a saturated 5 to 7 membered ring); and physiologically acceptable salts and solvates thereof. The compounds are potent and selective antagonists of the effect of 5-HT and 5-H₁ receptors. Solubility modulated drug delivery system.

ABSTRACT:

A drug delivery device for the controlled release of a therapeutically active ingredient into an environment of use is disclosed which comprises:

- (A) a core composition comprising
 - (a) a plurality of controlled release solubility modulating units comprising solubility modulating agents each of which is a complexing agent or a surfactant and which is either (i) surround by a water insoluble coat containing at least one pore forming additive dispersed throughout said coat, or (ii) dispersed in an intrinsically soluble and (iii) 0.1 to 75% by weight, based on the total weight of (i) and (ii), of at least one water leachable pore forming additive dispersed throughout said wall.

US-CL-CURRENT: 424/473, 482

US PAT NO: 4,939,144 IMAGE AVAILABLE- LS: 3 of 28
TITLE: Tricyclic ketone derivatives as 5-HT antagonists

ABSTRACT:

The invention relates to ketones of the general formula (I): #EGR1#E wherein L₁ represents an imidazolyl group of the formula: #EGR2#E one of the groups represented by R₁sub.1, R₁sub.2 and R₁sub.3 is a hydrogen atom or a C_nsub.1-6 alkyl, C_nsub.3-7 cycloalkyl, C_nsub.1-6 alkenyl, phenyl or phenylC_nsub.1-3 alkyl group, and each of the other two groups, which may be the same or different, represents a hydrogen atom or a C_nsub.1-6 alkyl group; n represents 1, 2 or 3; Q represents a hydrogen atom, a halogen atom, or a hydroxy, C_nsub.1-4 alkoxy, phenylC_nsub.1-3 alkoxy or C_nsub.1-6 alkyl group, or a group -NR₄sub.4 R₅sub.5 or -CONR₄sub.4 R₅sub.5, (wherein R₄sub.4 and R₅sub.5, which may be the same or different, each represents a hydrogen atom or a C_nsub.1-4 alkyl or C_nsub.3-4 alkenyl group, or together with sup.e, wherein R₅sub.5 represents a hydrogen atom or a group selected from C_nsub.1-10 alkyl, C_nsub.3-6 alkenyl, C_nsub.3-10 alkenyl, C_nsub.3-7 cycloalkyl, C_nsub.3-7 cycloalkyl C_nsub.1-6 alkyl, phenyl, phenylC_nsub.1-3 alkyl, -CO_nsub.1 R₆sub.7, -OR₇sub.7, -CONR₇sub.7 R₈sub.8 or -SO_nsub.2 R₉sub.9 (wherein R₆sub.7 and R₈sub.8, which may be the same or different, each represents a hydrogen atom, a C_nsub.1-6 alkyl, or C_nsub.3-7 cycloalkyl group, or a phenyl or phenylC_nsub.1-4 alkyl group, in which the phenyl group is optionally substituted by one or more C_nsub.1-4 alkyl, C_nsub.1-4 alkoxy or hydroxy groups or halogen atoms, with the proviso that R₆sub.7 does not represent a hydrogen atom when R₅sub.5 represents a group -CO_nsub.1 R₇sub.7); and physiologically acceptable salts and solvates thereof. The compounds are potent and selective antagonists of the effect of 5-HT and 5-H₁ receptors and are useful, for example, in the treatment of neuroleptic, antidepressant, anxiolytic and hypnotic disorders. 103

604/670/111 group or the formulae, wherein and the various substituents are defined hereinbelow. The compounds are potent and selective antagonists of the effect of 5-HT at 5-HT₂ receptors and are useful, for example, in the treatment of psychotic disorders, anxiety, and nausea and vomiting.
US-CL-CURRENT: 540/603; 546/200; 546/336

US PAT NO: 6,822,791 L5: 12 of 26
TITLE: Pharmaceutical compositions
of 2,2'-1,1'-bis-2,2'-(3,1-benzoxazin-4-one) ethylenes

ABSTRACT:

This invention relates to pharmaceutical compositions of compounds of the general formula: #STR1# wherein R₁ is an aryl group or a substituted aryl group wherein the substituent is halogen, hydroxy, C₁sub.(1-6) lower alkoxy, C₂sub.(1-6) lower alkyleneoxy, halo C₂sub.(1-6) lower alkyl, cyano, nitro, mono- or di-C₂sub.(1-6) alkylxino or C₂sub.(1-6) lower alkanoylamoine; or a 5-membered or 6-membered C₂sub.(1-6) alkyl substituted or unsubstituted heterocyclic group containing a heteroatom selected from oxygen, nitrogen, and sulfur, or a condensed heterocyclic group consisting of a heterocycle as defined above and a benzene nucleus, and R₂ and R_{2'} are, independently, hydrogen, halogen, nitro, C₂sub.(1-6) lower alkyl or C₂sub.(1-6) lower alkoxy. These compounds have been found to exhibit hyaluronidase inhibiting activity, ant4,814,183

L5: 13 of 26
TITLE: Device for the controlled release of drugs with
Donnan-like modulation by charged insoluble resins

ABSTRACT:

The instant invention is directed to a drug delivery device for the controlled release of beneficial agents and drugs into an environment of use comprising:

- (A) a core composition comprising
 - (a) a water insoluble, non-diffusible charged resin entity, and
 - (b) a diffusible, water soluble ionizable therapeutically active ingredient carrying the same charge as said resin entity; and
- (B) a substantially imperforate water-insoluble wall surrounding said core composition, prepared from a semipermeable material substantially impermeable to the core composition and permeable to the passage of an external fluid in the environment of use, with said wall having a hole(s) for release of the therapeutic agent through the water insoluble wall.

US-CL-CURRENT: 424/485, 443, 444, 486, 487, 488

US PAT NO: 4,806,581 L5: 14 of 26
TITLE: Imidazoyl- indenylpropanones as 5-HT₂ receptor antagonists

ABSTRACT:

The invention relates to compounds of the effect of 5-HT at 5-HT₂ receptors and are useful, for example, in the treatment of psychotic disorders, anxiety, and nausea and vomiting.

US-CL-CURRENT: 514/212, 322, 397; 540/603; 546/201; 546/336

US PAT NO: 4,795,544 L5: 15 of 26
TITLE: Device for pH independent release of drugs through the
Donnan-like influences of charged insoluble resins

ABSTRACT:

A device is disclosed for the controlled delivery of a beneficial agent. The agent is delivered to the environment surrounding the device at a substantially constant rate for a specified period with a reduced dependence on the environmental pH. The device is comprised of a core compartment containing (1) a charged, water insoluble, non-diffusible component and (2) at least one beneficial agent; (2). In operation the insoluble charged polymer resin (2) acts as a pH-dependent barrier

104

wave the same electro-static charge and do not form an ion exchange complex. Rather, a Donnan influenced mass transport phenomena of the beneficial agent is effected through the pores in the device, actuated by water from the environment, with migration of the freely mobile diffusible species (beneficial agent) away from the non-mobile species (charged entity). This effects the release of the beneficial agent through the wall at a controlled rate with reduced pH dependency.

US-CL-CURRENT: 424/468, 457, 474, 482

US PAT NO: 4,785,122 LS: 16 of 26
TITLE: Method for production of amine compound

ABSTRACT:

A method for the producing 2-(dialkylamino)alkyl-2-furanyl-methyl-thio-ethane amine by the reaction of cysteamine or cysteamine hydrochloride containing free hydrogen chloride with 5-(dialkylamino)alkyl furfuryl alcohol, which method can be obtained the product in a highly yield by carrying out said reaction at a temperature in the range of 30.degrees pharmaceutical preparation which is prepared as a pharmaceutical preparation comprising lower alkyl ether of cellulose, polyacrylic acid or its pharmaceutically acceptable salt, and active drugs, or a pharmaceutical preparation comprising lower alkyl ether of cellulose, polyacrylic acid or its pharmaceutically acceptable salt, and active drugs together with a foaming agent, so that it may release the active drugs by such slight degrees in the stomach or the intestinal tract as to make it possible to provide an adequate supply of active drugs in enough concentration to display their therapeutic value for many hours.

US-CL-CURRENT: 424/44, 91, 487, 482

US PAT NO: 4,755,579 LS: 16 of 28
TITLE: Fluoroalkoxy substituted benzimidazoles useful as gastric acid secretion inhibitors

ABSTRACT:

Dialkoxypyridines of formula I #STR1# wherein R1 is 1-3C-alkyl which is completely or predominantly substituted by fluorine, or a chlorodifluoromethyl radical and R1' is hydrogen, halo, trifluoromethyl, 1-3C-alkyl, or 1-3C-alkoxy which is optionally completely or predominantly substituted by fluorine, or R1 and R1', together with the oxygen atom to which R1 is bonded, are 1-3C-alkylenedioxy, which is optionally completely or partly substituted by fluorine, or chlorotrifluoroethylenedioxy, R3 is 1-3C-alkoxy, one of R2 and R4 is 1-3C-alkoxy and the other is a hydrogen atom or 1-3C-alkyl and n is 0 or 1, and salts thereof are new compounds with a pronounced protective action on the stomach. Processes for preparing these compounds, medicaments, pharmaceutical compositions [(1,3-dioxo-1,3-propanediyliid)imino-bisbenzoic acid derivatives and their use]

ABSTRACT:

Compounds of the general formula: #STR1# wherein A and B are both hydrogen, or one of A and B is a group (G) of the formula: #STR2# and the other is a group R.sup.5 wherein R.sup.1 is an aryl group or a heterocyclic group, both of them being optionally substituted, and R.sup.4 and R.sup.5 are both hydrogen or together form a single chemical bond, R.sup.2 and R.sup.3 are both hydrogen, and, where applicable, pharmaceutically acceptable salts thereof are hyaluronidase inhibitors, and useful as anti-allergic agent and anti-ulcerous agent. Among the compound (IV), those wherein when one of A and B is the group (G) and the other is the group R.sup.5 wherein R.sup.1 is a substituted aryl and R.sup.4 and R.sup.5 together form a single chemical bond, R.sup.1 is

$R_{1,2}^{sup.1}$ and $R_{1,2}^{sup.2}$ are independently carboxy or its functional derivative other than methyl ester, are novel.
 US-CL-CURRENT: 514/211, 218, 227.5, 230.5, 237.5, 255, 331, 357, 365,
 381, 394, 400, 415, 427, 438, 452, 466, 471, 485, 486, .
 522, 533, 563

US PAT NO: 4,686,250 LS: 20 of 26
 TITLE: Picoline derivative useful as gastric acid secretion inhibitors

ABSTRACT:

Picoline derivatives of the formula I ##STR1## wherein the substituents have the meanings given in the description, and their salts are new compounds having a pronounced protective action on the paring same are described by the invention. The prepared from and contains precipitated and undried magaldrate gel, a polyhydric **alcohol** and fluidizing amounts of a first and second fluidizer. One fluidizer is provided by an aluminum hydroxide gel having colloidal properties and the second by a pharmaceutically acceptable citrate ion source including citric acid. The process and composition are characterized in providing rehydratable antacid composition which when admixed with water forms a fluid, resuspendible, pharmaceutically elegant suspension possessing high antacid capacity and **stability** at even elevated magaldrate concentrations in addition to the ability to fluidize stiff, paste-like magaldrate gel cakes.
 US-CL-CURRENT: 424/689, 690

US PAT NO: 4,634,777 LS: 22 of 26
 TITLE: ((1,3-dioxo-1,3-propanediyl)dimino)-bisbenzoic acid derivatives

ABSTRACT:

Compounds of the general formula: ##STR1## wherein A and B are both hydrogen, or one of A and B is a group (G) of the formula: ##STR2## and the other is a group R._{2,3}, lower alkyl or lower alkoxy, and
 $R_{1,2}^{sup.3}$ and $R_{1,2}^{sup.3'}$ are independently carboxy or its functional derivative, with the proviso that (a) when A and B are both hydrogen,

104

then $R_{1,2}^{sup.1}$ and $R_{1,2}^{sup.2}$ cannot be both hydrogens, and, where applicable, pharmaceutically acceptable salts thereof are hydriodidase inhibitors, and useful as anti-allergic agents and anti-ulcerative agents. Among the compounds (I), those wherein both the R_{2,3}

R₁ and R₂ can also be the same or the groups R₁ and R₂ together form a single chemical bond, R₁ is unsubstituted aryl and R₂ is 04, 253, 325, 342, 495; 549/77, 362, 441, 496; 556/420; 560/21, 27, 37, 45, 47, 48; 562/435, 442, 453, 455, 456, 457; 564/153

US PAT NO: 4,590,192 LS: 23 of 26
TITLE: Benzothiazoles, their pharmaceutical compositions, and method of use

ABSTRACT:

Compounds of formula (I), or a pharmaceutically acceptable salt, quaternized derivative, N-oxide or solvate thereof:

R₁-Ar-(CH₂-sub-2)-sub-a-X-(CH₂-sub-2)-sub-b-NH-Het (I)
wherein: the substituents are defined in the specification.
The compounds are useful in treating excess gastric acid secretions such as peptic ulcers.

US-CL-CURRENT: 514/233.8, 321, 373; he oral sucrose, (2) a water-soluble protein, (3) a polyhydric alcohol, and (4) a fatty acid ester or/and a carboxyvinyl polymer, has various advantages such as good feeling in use, good retainability within the mouth, slow release, improved absorbability of drug through the mucosa, improved bioavailability, etc., and therefore can be used an excellent pharmaceutical preparation for administration to the mucous membrane of the mouth.

US-CL-CURRENT: 424/435, 81; 514/773, 774, 775

US PAT NO: 4,558,044 LS: 25 of 26
TITLE: 1,2,4-Benzothiadiazines

ABSTRACT:

Disclosed are compounds of the formula

R₁-Ar-(CH₂-sub-2)-sub-a-X-(CH₂-sub-2)-sub-b-NH-Het
wherein R₁ is guanidine or substituted guanidine, Ar is furandiyl, thiophendiyl, phenylene, propounds are useful for the treatment or prophylaxis of disorders relating to excess gastric acid secretion in mammals.

US-CL-CURRENT: 514/223.2, 222.8; 544/12, 13

US PAT NO: 4,432,983 LS: 26 of 26
TITLE: Conformationally restricted histamine H₂receptor antagonists containing a tropane ring

ABSTRACT:

Histamine H₂receptor, isothiazole, oxazole, isoxazole, triazole, thiadiazole, benzimidazole, or furan ring either unsubstituted or substituted with a C₁-C₄ alky, hydroxyl, trifluoromethyl, benzyl, halogen, amino, or dimethylaminomethyl group are disclosed along with a synthetic method of producing such compounds and their use as gastric-acid-production inhibitors.

US-CL-CURRENT: 514/304, 927; 544/234, 333, 405; 546/125

END

51 log y

U.S. Patent & Trademark Office LOGOFF AT 09:18:09 ON 06 DEC 20

L1 220 S RANITIDINE
L2 0 S ALCOHOL OR ETHANOL
L3 164400 S ALCOHOL OR ETHANOL, OR 2-PROPANOL
L4 192 S L1 AND L3
L5 26 S L4 AND STABILITY
L6 24 S L3 AND ORAL

=> d 15 L-26 ti ab ccls

US PAT NO: 4,968,507 [IMAGE AVAILABLE]
TITLE: Controlled porosity osmotic pump

LS: 1 of 26

ABSTRACT:

The instant invention is directed to an osmotic pump comprising:
(A) at least one active agent surrounded by
(B) a rate controlling water insoluble wall, having a fluid permeability of 6.96.times.10.sup.-18 to 6.96.times.10.sup.-14 cm.sup.3 sec/g and a reflection coefficient of less than 1, prepared from:
(i) a polymer permeable to water but impermeable to solute and
(ii) 0.1 to 60% by weight, based on the total weight of (i) and (ii), of at least one pH insensitive pore forming additive dispersed throughout said wall.

US-CL-CURRENT: 424/455, 473; 604/890.1; 892.1

US PAT NO: 4,963,546 [IMAGE AVAILABLE]

LS: 2 of 26

TITLE: Ketone derivatives which are antagonists of 5-HT at 5-HT_{sub}.3 receptors, compositions containing them, and method of use

ABSTRACT:

The invention relates to compounds of the general formula (I): #STR1# wherein R^{sup}.1 and R^{sup}.2 together form a C_{sub}.3-5 alkylene chain and R^{sup}.3 is a hydrogen atom; or R^{sup}.1 and R^{sup}.3 together form a C_{sub}.2-4 alkylene chain and R^{sup}.2 is a hydrogen atom; A-B represents the group R^{sup}.4 R^{sup}.5 C—CH_{sub}.2 or R^{sup}.4 C.dbd.CH; R^{sup}.4 and R^{sup}.5, which may be the same or different, each represent a hydrogen atom or a C_{sub}.1-6 alkyl group; and Ia represents an imidazolyl group of formula: #STR2# wherein one of the groups represented by R^{sup}.6, R^{sup}.7 and R^{sup}.8 is a hydrogen atom or a C_{sub}.1-6 alkyl, C_{sub}.3-7 cycloalkyl, C_{sub}.3-6 alkenyl, phenyl or phenylC_{sub}.1-3 alkyl group and each of the other two groups, which may be the same or different, represents a hydrogen atom or a C_{sub}.1-6 alkyl group; and physiologically acceptable salts and solvates thereof. The compounds are potent and selective antagonists of the effect of 5-HT at 5-HT_{sub}.3 receptors and are useful, for example in the treatment of psychotic disorders, anxiety, and nausea and vomiting.

US-CL-CURRENT: 514/214, 296, 411; 540/581; 546/94; 549/428

US PAT NO: 4,950,681 [IMAGE AVAILABLE]

LS: 3 of 26

TITLE: Ketone derivatives

ABSTRACT:

The invention relates to ketones of the general formula (I): #STR1# wherein R^{sup}.1 represents a hydrogen atom or a group selected from C_{sub}.1-6 alkyl, C_{sub}.3-6 alkenyl, C_{sub}.3-10 alkynyl, C_{sub}.3-7 cycloalkyl, C_{sub}.3-7 cycloalkylC_{sub}.1-4 alkyl, phenyl or phenylC_{sub}.1-4 alkyl in which the phenyl group is optionally substituted by one or more C_{sub}.1-4 -alkyl, C_{sub}.1-4 alkoxy or hydroxy groups or halogen atoms, with the proviso that R^{sup}.8 does not represent a hydrogen atom when R^{sup}.1 represents a group —CO_{sub}.2 R^{sup}.8 or —SO_{sub}.2 R^{sup}.8; R^{sup}.2 represents a hydrogen atom or a C_{sub}.1-6 alkyl, C_{sub}.3-6 alkenyl, C_{sub}.3-7 cycloalkyl, phenyl or phenylC_{sub}.1-3 alkyl group; R^{sup}.3 and R^{sup}.4 which can be the same or different, each representing

108

G 000225

G 000226

[45] Date of Patent: Nov. 26, 1991

[54] AQUEOUS RANITIDINE COMPOSITIONS STABILIZED WITH ETHANOL

[75] Inventor: David R. Long, Royston, England

[73] Assignee: Glaxo Group Limited, London, England

[21] Appl. No.: 494,804

[22] Filed: Mar. 14, 1990

Related U.S. Application Data

[63] Continuation of Ser. No. 344,620, Apr. 28, 1989, abandoned, which is a continuation of Ser. No. 131,442, Dec. 11, 1987, abandoned.

[30] **Foreign Application Priority Data**

Dec. 12, 1986 [GB] United Kingdom 86 29781

[51] Int. CL⁵ A61K 31/34

[52] U.S. Cl. 514/471

[58] Field of Search 514/461, 471

[56] **References Cited**

FOREIGN PATENT DOCUMENTS

2547727 12/1984 France

2120938 5/1983 United Kingdom

2142820 1/1985 United Kingdom

OTHER PUBLICATIONS

Chem. Abst. (97)-61014G (1982).

Chem. Abst. (104)-102280Z (1986).

Primary Examiner—Frederick E. Waddell

Assistant Examiner—Diane Gardner

Attorney, Agent, or Firm—Bacon & Thomas

[57] **ABSTRACT**

The stability of aqueous formulations of ranitidine or a physiologically acceptable salt thereof is enhanced by the addition of ethanol.

12 Claims, No Drawings

611

G 000227

1

AQUEOUS RANITIDINE COMPOSITIONS STABILIZED WITH ETHANOL

This application is a continuation of application Ser. No. 07/344,620, filed Apr. 28, 1989, now abandoned, which is a continuation of Ser. No. 07/131,442, filed Dec. 11, 1987, now abandoned.

The present invention relates to a pharmaceutical composition containing as active ingredient the histamine H₂ antagonist ranitidine.

Ranitidine, [N-[2-[[[5-(dimethylamino)methyl-2-furanyl]methyl]thio]ethyl]-N'-methyl-2-nitro-1,1-ethenediamine, and its physiologically acceptable salts are described in British Patent Specification No. 1565966. In that specification there is reference to liquid formulations for oral and parenteral administrations and there is a description of an aqueous based formulation for intravenous use and another of an oral syrup. Both of these formulations contained sufficient hydrochloric acid to achieve a pH of 5.0 and the syrups also contained Sorbitol solution BPC and a flavour as required.

British Patent Application No. GB 2142820A describes aqueous based formulations containing ranitidine and/or one or more of its physiologically acceptable salts thereof having a pH within the range 6.5-7.5. In that specification there is reference to liquid formulations for oral and parenteral administration and there are examples of aqueous formulations for intravenous and oral use. These formulations contain ranitidine hydrochloride and are buffered to a pH of approximately 7 and for intravenous administration the formulations also contain phenol or sodium chloride. For oral administration the formulation also contains hydroxypropyl-methyl cellulose as a viscosity enhancing agent, a preservative (parabens), a sweetening agent and a flavour. These compositions have a significantly greater shelf-life over those in British Patent No. 1565966.

We have now surprisingly found that the stability of ranitidine in aqueous based formulations and more particularly aqueous based formulations for oral administration may be substantially enhanced by the addition of ethanol to the formulation.

Thus the present invention provides a pharmaceutical composition which is an aqueous formulation of ranitidine and/or one or more physiologically acceptable salts thereof also containing ethanol. The aqueous formulation is prepared using ingredients of a purity such that it is suitable for administration to patients and will in general contain at least one conventional pharmaceutical excipient in addition to the ethanol and ranitidine and/or physiologically acceptable salts thereof.

The amount of ethanol present in the formulation is such that the resulting formulation has the enhanced stability. Preferably the amount of ethanol in the composition on a weight/volume basis of the complete formulation, is within the range 2.5% to 10%, and more particularly is between 5 to 10% w/v, more especially 7-8% w/v.

Preferred compositions according to the invention are those in which the pH of the aqueous formulation is within the range 6.5 to 7.5, particularly 6.8 to 7.4 and more especially 7 to 7.3. The required pH of the formulation is preferably obtained by the use of suitable buffer salts for example, potassium dihydrogen orthophosphate and disodium hydrogen orthophosphate or citric acid and disodium hydrogen orthophosphate.

2

A preferred embodiment of the invention is an aqueous formulation for oral administration. Such a formulation may comprise ranitidine and/or one or more of its physiologically acceptable salts dissolved in water, ethanol, a preservative and a viscosity enhancing agent. Preferably the required pH of the formulation is obtained by the use of appropriate buffer salts. Optionally the composition may also contain other conventional excipients such as a sweetener, a flavour and/or flavouring aids.

Examples of suitable preservatives include one or more alkyl hydroxybenzoates such as methyl, ethyl, propyl and/or butyl hydroxybenzoates.

Examples of suitable viscosity enhancing agents include Xanthan gum, sorbitol glycerol, sucrose or a cellulose derivative such as carboxymethylcellulose or a salt thereof of a C₁₋₄ alkyl and/or a hydroxy-C₂₋₄ alkyl ether of cellulose such as methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxyethylmethylcellulose and hydroxypropylmethylcellulose.

Examples of suitable sweeteners include saccharin sodium, sodium cyclamate, sorbitol and sucrose.

Examples of suitable flavouring agents include 'mint' flavours such as peppermint flavouring agents.

The concentration of ranitidine in the oral formulation, expressed as free base, is conveniently within the range 20-400 mg per 10 ml, for example 20-200 mg per 10 ml, more particularly 150 mg per 10 ml dose.

The amount of ethanol in the formulation for oral administration, expressed as a percentage of the complete formulation on a weight/volume basis, is preferably within the range 2.5 to 10%, and more particularly between 5 to 10%, more especially 7-8%.

The amount of viscosity enhancing agent in the formulation will preferably be sufficient to give a solution with a viscosity in the range of 10 to 100 centipoises.

The aqueous formulations for oral administration are conveniently prepared by mixing an aqueous solution of ranitidine and/or one or more of its physiologically acceptable salts together with ethanol and the excipients, with aqueous solution or dispersion of the viscosity enhancing agent.

The aqueous formulations according to the invention are preferably prepared using ranitidine in the form of its hydrochloride salt.

An illustrative example of a formulation according to the invention is as follows. In this example the relative proportions of ranitidine hydrochloride and the buffer salts are such that the formulation has a pH of approximately 7.

Ranitidine oral liquid formulation (150 mg/10 ml) expressed as free base		% w/v
Ranitidine hydrochloride		1.68
Ethanol		7.5
Potassium dihydrogen orthophosphate		0.095
Disodium hydrogen orthophosphate anhydrous		0.350
Hydroxypropylmethylcellulose	qs	
Preservative	qs	
Sweetening agents	qs	
Flavour	qs	
Purified water BP to		100 ml

I claim:

1. A pharmaceutical composition which is an aqueous formulation for oral administration of an effective

5,068,249

3

amount of ranitidine and/or one or more physiologically acceptable salts thereof. said formulation comprising a stabilizing effective amount of ethanol and said composition having a pH in the range of 6.5-7.5.

2. A pharmaceutical composition according to claim 1 containing 2.5% to 10% weight/volume ethanol based on the complete formulation.

3. A pharmaceutical composition according to claim 1 containing 7% to 8% weight/volume ethanol based on the complete formulation.

4. A pharmaceutical composition according to claim 1 having a pH in the range 6.8 to 7.4.

5. A pharmaceutical composition according to claim 1 having a pH in the range 7.0 to 7.3.

6. A pharmaceutical composition according to claim 1 wherein said pH is obtained by the use of buffer salts.

7. A pharmaceutical composition according to claim 1 prepared using ranitidine in the form of the hydrochloride salt.

4

8. A pharmaceutical composition as claimed in claim 1, wherein the effective amount is 20-400 mg ranitidine per 10 ml dose expressed as free base.

9. A pharmaceutical composition as claimed in claim 1, wherein the effective amount is 20-200 mg ranitidine per 10 ml dose expressed as free base.

10. A pharmaceutical composition as claimed in claim 1, wherein the effective amount is 150 mg ranitidine per 10 ml dose expressed as free base.

11. A pharmaceutical composition which is an aqueous formulation of ranitidine suitable for oral administration containing 150 mg ranitidine per 10 ml dose expressed as free base, said formulation having a pH in the range 7.0 to 7.3 and also containing 7% to 8% weight/volume ethanol based on the complete formulation.

12. A pharmaceutical composition according to claim 11 wherein said pH is obtained by the use of buffer salts.

20

25

30

35

40

45

50

55

60

65

G 000229

Staple Issue Slip Here

INDEX OF CLAIMS

Claim	Date
1	
2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	
61	
62	
63	
64	
65	
66	
67	
68	
69	
70	
71	
72	
73	
74	
75	
76	
77	
78	
79	
80	
81	
82	
83	
84	
85	
86	
87	
88	
89	
90	
91	
92	
93	
94	
95	
96	
97	
98	
99	
100	
101	
102	
103	
104	
105	
106	
107	
108	
109	
110	
111	
112	
113	
114	
115	
116	
117	
118	
119	
120	
121	
122	
123	
124	
125	
126	
127	
128	
129	
130	
131	
132	
133	
134	
135	
136	
137	
138	
139	
140	
141	
142	
143	
144	
145	
146	
147	
148	
149	
150	
151	
152	
153	
154	
155	
156	
157	
158	
159	
160	
161	
162	
163	
164	
165	
166	
167	
168	
169	
170	
171	
172	
173	
174	
175	
176	
177	
178	
179	
180	
181	
182	
183	
184	
185	
186	
187	
188	
189	
190	
191	
192	
193	
194	
195	
196	
197	
198	
199	
200	
201	
202	
203	
204	
205	
206	
207	
208	
209	
210	
211	
212	
213	
214	
215	
216	
217	
218	
219	
220	
221	
222	
223	
224	
225	
226	
227	
228	
229	
230	
231	
232	
233	
234	
235	
236	
237	
238	
239	
240	
241	
242	
243	
244	
245	
246	
247	
248	
249	
250	
251	
252	
253	
254	
255	
256	
257	
258	
259	
260	
261	
262	
263	
264	
265	
266	
267	
268	
269	
270	
271	
272	
273	
274	
275	
276	
277	
278	
279	
280	
281	
282	
283	
284	
285	
286	
287	
288	
289	
290	
291	
292	
293	
294	
295	
296	
297	
298	
299	
300	
301	
302	
303	
304	
305	
306	
307	
308	
309	
310	
311	
312	
313	
314	
315	
316	
317	
318	
319	
320	
321	
322	
323	
324	
325	
326	
327	
328	
329	
330	
331	
332	
333	
334	
335	
336	
337	
338	
339	
340	
341	
342	
343	
344	
345	
346	
347	
348	
349	
350	
351	
352	
353	
354	
355	
356	
357	
358	
359	
360	
361	
362	
363	
364	
365	
366	
367	
368	
369	
370	
371	
372	
373	
374	
375	
376	
377	
378	
379	
380	
381	
382	
383	
384	
385	
386	
387	
388	
389	
390	
391	
392	
393	
394	
395	
396	
397	
398	
399	
400	
401	
402	
403	
404	
405	
406	
407	
408	
409	
410	
411	
412	
413	
414	
415	
416	
417	
418	
419	
420	
421	
422	
423	
424	
425	
426	
427	
428	
429	
430	
431	
432	
433	
434	
435	
436	
437	
438	
439	
440	
441	
442	
443	
444	
445	
446	
447	
448	
449	
450	
451	
452	
453	
454	
455	
456	
457	
458	
459	
460	
461	
462	
463	
464	
465	
466	
467	
468	
469	
470	
471	
472	
473	
474	
475	
476	
477	
478	
479	
480	
481	
482	
483	
484	
485	
486	
487	
488	
489	
490	
491	
492	
493	
494	
495	
496	
497	
498	
499	
500	
501	
502	
503	
504	
505	
506	
507	
508	
509	
510	
511	
512	
513	
514	
515	
516	
517	
518	
519	
520	
521	
522	
523	
524	
525	
526	
527	
528	
529	
530	
531	
532	
533	
534	
535	
536	
537	
538	
539	
540	
541	
542	
543	
544	
545	
546	
547	
548	
549	
550	
551	
552	
553	
554	
555	
556	
557	
558	
559	
560	
561	
562	
563	
564	
565	
566	
567	
568	
569	
570	
571	
572	
573	
574	
575	
576	
577	
578	
579	
580	
581	
582	
583	
584	
585	
586	
587	
588	
589	
590	
591	
592	
593	
594	
595	
596	
597	
598	
599	
600	
601	
602	
603	
604	
605	
606	
607	
608	
609	
610	
611	
612	
613	
614	
615	
616	
617	
618	
619	
620	
621	
622	
623	
624	
625	
626	
627	
628	
629	
630	
631	
632	
633	
634	
635	
636	
637	
638	
639	
640	
641	
642	
643	
644	
645	
646	
647	
648	
649	
650	
651	
652	
653	
654	
655	
656	
657	
658	
659	
660	
661	
662	
663	
664	
665	
666	
667	
668	
669	
670	
671	
672	
673	
674	
675	
676	
677	
678	
679	
680	
681	
682	
683	
684	
685	
686	
687	
688	
689	
690	

SEARCHED

Class	Sub.	Date	Exmr.
514	461	6/12/87	42
		11/11/89	

SEARCH NOTES

Co on long (Parent)	Date	Exmr.
Par. 13/442-120	6/12/87	

INTERFERENCE SEARCHED

Class	Sub.	Date	Exmr.

G 000231

APPROVED FOR LICENSE

MAY 10 8 89 26

SEARCHED
SERIALIZED
INDEXED
FILED
MAY 11 1989Received
or
MailedEntered
or
Counted

CONTENTS

1. Application	papers.
2. <u>All Crdit A</u>	<u>4-28-89</u>
3. <u>R3mrs</u>	<u>June 28 89 4/61</u>
4. <u>leg Time get</u>	<u>Oct. 30, 1989</u>
5. <u>Credit B + Prior Act</u>	<u>Oct. 30, 1989</u>
6. <u>FIR 3mo</u>	<u>Nov. 14, 1989 11/13</u>
7. <u>leg Time get</u>	<u>Nov. 14, 1990</u>
8.	
9.	
10.	
11.	
12.	
13.	
14.	
15.	
16.	
17.	
18.	
19.	
20.	
21.	
22.	
23.	
24.	
25.	
26.	
27.	
28.	
29.	
30.	
31.	
32.	

G 000232

Staple Issue Slip Here

INDEX OF CLAIMS

Claim	Date
1	7/7/97
2	7/7/97
3	7/7/97
4	7/7/97
5	7/7/97
6	7/7/97
7	7/7/97
8	7/7/97
9	7/7/97
10	7/7/97
11	7/7/97
12	7/7/97
13	7/7/97
14	7/7/97
15	7/7/97
16	7/7/97
17	7/7/97
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	
61	
62	
63	
64	
65	
66	
67	
68	
69	
70	
71	
72	
73	
74	
75	
76	
77	
78	
79	
80	
81	
82	
83	
84	
85	
86	
87	
88	
89	
90	
91	
92	
93	
94	
95	
96	
97	
98	
99	
100	

Claim	Date
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	
61	
62	
63	
64	
65	
66	
67	
68	
69	
70	
71	
72	
73	
74	
75	
76	
77	
78	
79	
80	
81	
82	
83	
84	
85	
86	
87	
88	
89	
90	
91	
92	
93	
94	
95	
96	
97	
98	
99	
100	

G 000233

SEARCHED			
Class	Sub.	Date	Exmr.
514	461	4/29/90	
514	471	5/29/91	DG

SEARCH NOTES		
	Date	Exmr.
Cass on line parents	4/29/90	
parents	12/6/90	DG
APS	12/6/90	DG

INTERFERENCE SEARCHED			
Class	Sub.	Date	Exmr.
514	471	5/29/91	DG

115W

G 000234

17/490804

RECORDED FOR LICENSEE

RECEIVED

90 APR 16 AM 8:59

GROUP 120

Received
or
Mailed

15

Entered
or
Counted

CONTENTS

1. Application	papers.	
2. <i>Cantt C</i>		
3. <i>Rejected 3 mos.</i>	04 MAY 1990	4/30
4. <i>Reg Time 3 mos.</i>	Oct. 31, 1990	
5. <i>Cantt D</i>	Oct. 31, 1990	
6. <i>Price Act Stated (cont)</i>	Oct. 31, 1990	
7. <i>Disclosure Statement</i>	1-10-91/8	
8. <i>MDS Section</i>	1/22/91/8	
9. <i>Reg Time 1 mo.</i>	May 10, 1991	
10. <i>Reg Recov. + Decl.</i>	May 10, 1991	
11. <i>PROGANT May 26 1991</i>	May 26, 1991	
12.		
13.		
14.		
15.		
16.		
17.		
18.		
19.		
20.		
21.		
22.		
23.		
24.		
25.		
26.		
27.		
28.		
29.		
30.		
31.		
32.		
33.		
34.		
35.		
36.		
37.		
38.		
39.		
40.		

114